mRNA could comprise a generic vaccine to be used for cancer, Elizabeth Tracey reports
Update: 2025-11-03
Description
If you were being treated for lung cancer or melanoma with immunotherapy and you received a Covid vaccine, you got a surprising benefit: you were twice as likely to survive your cancer as those who did not get a vaccine, a recent study found. Jeff Coller, an mRNA expert at Johns Hopkins, says the result suggests a nonspecific vaccine could be a game changer in cancer treatment.
Coller: This study basically is saying we could make a generic mRNA that's really going to excite the immune system to attack tumors. Because science builds upon itself we have technologies that are showing such promise. Because of politicalization of that technology and misunderstanding and mis- and disinformation around that technology we're seeing decisions being made which are potentially cutting off the American public from access to this type of medicine, which really could cure some of the most devastating cancers. :29
This study demonstrated the utility of the mRNA vaccine in lung cancer and melanoma, both associated with poor prognoses in more advanced stages. At Johns Hopkins, I’m Elizabeth Tracey.
Coller: This study basically is saying we could make a generic mRNA that's really going to excite the immune system to attack tumors. Because science builds upon itself we have technologies that are showing such promise. Because of politicalization of that technology and misunderstanding and mis- and disinformation around that technology we're seeing decisions being made which are potentially cutting off the American public from access to this type of medicine, which really could cure some of the most devastating cancers. :29
This study demonstrated the utility of the mRNA vaccine in lung cancer and melanoma, both associated with poor prognoses in more advanced stages. At Johns Hopkins, I’m Elizabeth Tracey.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
